###### Strengths and limitations of this study

-   The breadth of the comprehensive systematic literature search is a strength of this study.

-   To our knowledge, this is the first study where a meta-analysis and study quality assessment was performed on stroke prediction models in patients with diabetes.

-   We were only able to use C-statistics to compare the model performance, which might be insensitive to identify differences in models' ability to accurately risk-stratify patients into clinically meaningful risk groups.

Introduction {#s1}
============

Stroke, also known as a cerebrovascular accident, is the third leading cause of disability and accounted for over 6 million deaths worldwide in 2015.[@R1] Diabetes mellitus, characterised by chronic hyperglycaemia due to an absolute or relative deficiency in insulin, is a major risk factor for stroke. People with diabetes are at a twofold- to fivefold increased risk for stroke compared with people without diabetes.[@R3] Large clinical trials performed in people with diabetes supports the need for targeted cardiovascular risk reduction strategies to prevent the onset, recurrence and progression of acute stroke.[@R8]

Risk prediction models are statistical tools to estimate the probability that an individual with specific risk factors (eg, diabetes mellitus) will develop a future condition, such as stroke, within a certain time period (eg, 5 years).[@R9] Such tools for the estimation of stroke risk are frequently used to assist in decisions about clinical management for both individuals and populations. Accurate risk prediction of stroke is thus necessary to provide patients with accurate information on the expected benefit from a therapy or intervention. The importance of well-performing prediction models is increasingly being recognised and health researchers continue to develop parsimonious risk prediction models under different scenarios to meet this demand. Model performance statistics, such as C-statistic or AUC (area under the receiver operating characteristic curve) are indicators frequently used to identify models with the best predictive ability. These metrics can be compared and assessed through a formal systematic review and meta-analysis. Performing a systematic review and meta-analysis can also provide a comprehensive quantitative summary of the predictive ability of these models and evaluate their predictive performance within the available literature.

Risk factors for stroke include lifestyle-related factors,[@R10] predisposing medical conditions,[@R10] specific genetic diseases,[@R13] as well as sociodemographic factors.[@R11] Over the past decade, a number of prediction models (or risk scores) have been developed incorporating these risk factors to predict a person's risk of developing stroke.[@R15] Prediction of stroke is important for a number of reasons: to detect or screen high-risk subjects to prevent developing stroke through early interventions, to facilitate patient--doctor communication based on more objective information and to help patients to make an informed choice regarding their treatment. While multiple stroke prediction models have been proposed in patients with diabetes, little is known about which is the most accurate one. There has also been a lack of consistency in estimating risk across these different models. With this in mind, we aimed to systematically identify all prediction models for stroke that have been applied to patients with diabetes. We characterised the study populations in which these models were derived and validated. We also assessed the predictive performance and generalisability of these stroke prediction models so that the selection of models for clinical implementation can be informed.

Methods {#s2}
=======

Data sources and searches {#s2-1}
-------------------------

Similar to previously employed methodology,[@R16] we searched MEDLINE, EMBASE and PubMed (from database inception to 22 April 2019) for studies predicting the risk of stroke among patients with diabetes. We also searched the reference lists of all identified relevant publications. The search strategy focused on three key elements: diabetes, risk prediction with specific names of known risk scores and stroke. Only studies published in English were considered. The detailed search strategy is given in [online supplemental table S1](#SP1){ref-type="supplementary-material"}.
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Study selection {#s2-2}
---------------

Eligible articles were identified by two reviewers independently using a two-step process. First, an initial screen of titles and abstracts was performed. Abstract were retained if they reported data from an original study and reported on the development and/or validation of a stroke risk prediction model for patients with type 2 diabetes. We defined a stroke risk prediction model as one combining two or more independent variables to obtain estimates of the predicted risk for developing stroke. We considered any clinical-based or laboratory-based definition of stroke. Selected abstracts were further screened based on a full-text review. We used broad inclusion criteria to provide an extensive systematic review of the topic. There were no restrictions on study design (eg, cohort study, case--control study), geographic region or age ranges. Studies that developed prediction models for stroke in populations with type 2 diabetes and in the general population were included; however, models that were developed in the general population but did not validate their model in a type 2 diabetes population or models developed on a type 1 diabetes population were excluded. A study was included if the outcome of the prediction model was any type of stroke or stroke that was part of a composite cardiovascular disease (CVD) outcome, but excluded if the outcome was any other cardiovascular conditions (eg, coronary heart disease (CHD), coronary artery disease (CAD), heart failure). We excluded studies that did not predict stroke. Studies on recurrent stroke or other vascular conditions (eg, patients with hypertension) were also excluded. Studies that focused only on the added predictive value of new risk factors to an existing prediction model without reporting the performance of the existing model were excluded. Studies on score-based tools, such as risk charts were also excluded. Agreement between reviewers at the full-text stage was quantified using the kappa statistic. Any disagreement between reviewers was solved through consensus.

Data extraction {#s2-3}
---------------

Data were extracted from the finally selected studies using a standardised form by two reviewers. Information collected from each study included, outcome of the prediction model, location where the model was developed, predictors included in the model, age and gender of the study participants, number of events, duration of follow-up, modelling method used, measures of discrimination and calibration of the prediction model and the external validation of the prediction model. For the external validation studies, a different data extraction sheet was used. The collected information included specifics of the validation population, number of events, type of outcome, statistical tests and measures of discrimination, and calibration of the prediction model. Study quality was assessed using the CHARMS (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) Checklist.[@R17] The following items were evaluated for each study: Was inclusion/exclusion criteria for study participants specified?; Was there non-biased selection of study participants?; Did the authors discuss or consider missing values/information?; Was there blinded assessment of the outcome?; Was duration of follow-up adequate?; Were modelling assumptions satisfied?; Was the model externally validated? and Was the potential clinical utility of the model discussed in light of study limitations?

Data analysis {#s2-4}
-------------

The selection process for this systematic review and meta-analysis is summarised using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram.[@R18] Discrimination is defined as any assessment of the ability of the model to differentiate between subjects who will develop stroke from those who will not. The discrimination of a prediction model is often assessed using the concordance or C-statistic (also known as AUC). Calibration is defined as any report of the agreement between predicted probabilities and observed probabilities. Calibration is assessed using goodness-of-fit tests (eg, Hosmer-Lemeshow test), calibration slopes, tabular or graphical comparisons of predicted versus observed values within groupings of predicted risk or calibration plots. In studies that only provided a C-statistic but no measure of its variance, the SE and 95% CI of the AUC (C-statistic) was calculated using the formula:

$${SE}\left( {AUC} \right) = \sqrt{\frac{{AUC}\left\lbrack {1 - {AUC}} \right\rbrack + \left\lbrack {N_{1} - 1} \right\rbrack \times \left\lbrack {{AUC}/\left( {2 - {AUC}} \right) - {AUC}^{2}} \right\rbrack + \left\lbrack {N_{2} - 1} \right\rbrack \times \left\lbrack {2{AUC}^{2}/\left( {1 + {AUC}} \right) - {AUC}^{2}} \right\rbrack}{\left( {N_{1} \times N_{2}} \right)}}$$

where $N_{1} =$ the number of patients with stroke and $N_{2} =$ the number of patients without stroke and the upper 95% CI $= {AUC} + \left\lbrack {1.96 \times {SE}\left( {AUC} \right)} \right\rbrack$, and lower 95% CI $= {AUC} - \left\lbrack {1.96 \times {SE}\left( {AUC} \right)} \right\rbrack$.[@R19] The summary statistic from the individual studies was the C- statistic or AUC. We grouped studies based on the outcome of the risk prediction models developed in diabetes populations, whether stroke was the primary outcome of the model or stroke was a part of composite CVD outcome. Random effects meta-analysis was used to obtain the pooled weighted average C-statistic with 95% CIs for common groups of models using the DerSimonian and Laird method.[@R20] Heterogeneity was assessed using the Cochran Q and the I^2^ statistic and was explored using meta-regression and stratified analyses according to model outcomes. Small study effects were examined using funnel plots and Begg's test. The analyses were performed using Stata version 13.1 (Stata, College Station, Texas, USA) using the metan, metareg, metabias and metafunnel commands.

Patient and public involvement {#s2-5}
------------------------------

There was no direct patient or public involvement in this review.

Results {#s3}
=======

The search retrieved 21 797 citations (after duplicate removal) with an additional 63 potentially relevant papers retrieved from our grey literature search. After title and abstract screening, 262 studies were selected for full-text screening. After examining the full-text papers, 56 studies remained (reasons for exclusion stated in [figure 1](#F1){ref-type="fig"}), describing 38 models predicting stroke in patients with diabetes. Agreement between reviewers on the final articles eligible for inclusion in the systematic review was good (κ=0.83). Of these 38 models, 34 were specifically developed in patients with diabetes and 4 were developed in the general population but later externally validated in patients with diabetes. Among the models developed in patients with diabetes, nine models reported their outcome as stroke and presented a corresponding performance measure (C-statistic) for the models. Twenty-three models reported their outcome as a composite CVD outcome where stroke was one of the components and presented the model's performance measure (C-statistic) for the composite CVD outcome. Among the models developed in the general population, one model reported its outcome as stroke and three models reported a composite CVD outcome, which included stroke. Of these 38 prediction models, 17 were validated by 33 studies (some studies validated more than one model in the same study), of which 10 models had multiple validations, 7 models had a single validation and 21 models were not validated. Among the models with multiple validations, eight models were developed in a diabetes population (validated by 31 studies) and two were developed in the general population (validated by four studies). United Kingdom Prospective Diabetes Study (UKPDS) Risk Engine for Stroke by Kothari *et al* [@R21] was the most validated risk score (validated by 12 studies). [Figure 1](#F1){ref-type="fig"}, describes the systematic selection process of studies presenting a stroke prediction model applicable to patients with diabetes.

![PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram for systematic review of studies presenting stroke prediction models developed or validated in individuals with diabetes.](bmjopen-2018-025579f01){#F1}

Predicting the risk of stroke within models developed in populations with diabetes {#s3-1}
----------------------------------------------------------------------------------

[Table 1](#T1){ref-type="table"} describes the study characteristics of the nine risk prediction models developed in diabetes populations and presented a corresponding performance measure. The number of participants ranged from 1748 to 26 140 in the model development. The outcome of most models was stroke regardless of type. Duration of follow-up (total/median/mean) ranged from 501 days to 10.5 years with six models having ≥5 years of follow-up (defined as long duration) and three models with \<5 years of follow-up. Most of the prediction models were developed using Cox proportional hazards modelling techniques. The number of predictors included in the prediction models ranged from 4 to 29 with an average of 11 predictors per model. Several predictors were common to multiple models including age, sex, duration of diagnosed diabetes, systolic blood pressure and haemoglobin A1c (HbA1c). Only two models were externally validated after their development and four of them had never been validated in an external population. Calibration of the prediction model was reported by six studies (most commonly using the Hosmer-Lemeshow test). Discrimination was assessed using the C-statistic (or AUC) and reported by six models with values ranging from 0.64 to 0.80. The median C-statistic of the models was 0.71 with a large amount of unexplained heterogeneity in the discriminative performance of these models (I^2^=94.6%; Cochran Q-statistic p\<0.001; [figure 2](#F2){ref-type="fig"}). Stratifying pooled results by sample size (small vs large, p=0.19), follow-up time (short vs long, p=0.60), variables included in the model (few vs many, p=0.24) and geographic location (Asia vs others, p=0.60) did not explain the observed heterogeneity in the discriminative performance of these models. The discriminative ability of the model by Kiadaliri *et al* [@R22] was highest (C-statistic=0.80). The funnel plot and Begg's test (p\>0.999) suggested the absence of small study effects, with no correlation between studies of smaller cohorts reporting higher C-statistics ([online supplemental figure S1](#SP1){ref-type="supplementary-material"}).

![Forest plot of C-statistics, with 95% CIs of risk prediction models when outcome was reported for stroke.](bmjopen-2018-025579f02){#F2}

###### 

Characteristics of prediction models when outcome and corresponding performance measure (C-statistic) were reported for stroke

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Location           Outcome                                                                                                                                                                                                                                                                                No of Predictors                                                                                                                                                                                                                                                                                            Age                                   Gender                 Events (n)/total participants (n)                                                             Duration of follow-up                                                          Modelling method                                                Calibration                                                                                                                                  Discrimination (with CI)                                                                                                             External Validation
  ------------------------------------ ------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- ---------------------- --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ --------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ---------------------
  Yang *et al* [@R38]                  Hong Kong, China   Stroke (stroke or deaths from stroke), haemorrhagic stroke and ischaemic stroke                                                                                                                                                                                                        4 (age, A1C, spot urine ACR and history of CHD)                                                                                                                                                                                                                                                             Median age 57 years                   Both male and female   372/7209                                                                                      Median follow-up 5.37 years                                                    Cox proportional hazard model                                   The Life Table Method. Adequate calibration, value NR.                                                                                       Adjusted: AUROC=0.776 (considering follow-up time and censoring); unadjusted AUROC=0.749 (0.716 to 0.782)                            No

  Kothari *et al* [@R21]               UK                 Stroke (defined as a neurological deficit with symptoms or signs lasting 1 month or more)                                                                                                                                                                                              7 (duration of diabetes, age, sex, smoking, systolic blood pressure, total cholesterol to high-density lipoprotein cholesterol ratio and presence of atrial fibrillation)                                                                                                                                   25 to 65 years                        Both male and female   188/4549                                                                                      Median follow-up 10.5 years                                                    Maximum likelihood estimation using the Newton-Raphson method   NR                                                                                                                                           NR                                                                                                                                   Yes

  Wells *et al* [@R47]                 USA                CHD, heart failure, stroke, mortality                                                                                                                                                                                                                                                  29 (different variables for different models)                                                                                                                                                                                                                                                               18 years of age or older              Both male and female   Stroke: 1088/26 140                                                                           Median follow-up 501 days (Stroke model)                                       Competing risks regression model                                Calibration plot (predicted risk against actual risk): less-well calibration (stroke and mortality)                                          C-statistic=0.6881 (stroke)                                                                                                          No

  Stevens *et al*. UKPDS 66[@R24]      UK                 MI case fatality and stroke case fatality                                                                                                                                                                                                                                              5 (sex, HbA1c, SBP, previous stroke, white cell count for Stroke model)                                                                                                                                                                                                                                     Between 25 and 65 years               Both male and female   Stroke: 234/5102                                                                              Median follow-up of 7 years                                                    Stepwise selection algorithm                                    HL test: p=0.248 (Stroke model)                                                                                                              NR                                                                                                                                   No

  Tanaka *et al*JJ Risk Engine[@R48]   Japan              CHD, stroke, non-cardiovascular mortality, overt nephropathy and progression of retinopathy                                                                                                                                                                                            11 (sex, age, HbA1c, years after diagnosis, BMI, non-HDL cholesterol, ACR, atrial fibrillation, current smoker and leisure-time physical activity)                                                                                                                                                          40--84 years                          Both male and female   Stroke: 89/1748                                                                               Median follow-up of 7.2 years                                                  Cox regression model                                            HL test: p=0.12 (Stroke model)                                                                                                               C-statistic=0.636 (0.564 to 0. 708) (Stroke model)                                                                                   No

  Palmer *et al* (IRS)[@R23]           Scotland           Fatal or non-fatal stroke                                                                                                                                                                                                                                                              5 genotypes (IL-6 GG/GC, MCP- 1 GG, ICAM-1 EE, sel·E RR and MMP-3 5A5A)                                                                                                                                                                                                                                     Mean age 64.5±11.7 years              Both male and female   108/2182                                                                                      Mean follow-up of 6.2±1.1 years                                                Cox regression model                                            NR                                                                                                                                           NR                                                                                                                                   No

  Kiadaliri *et al* [@R22]             Sweden             First and second events of: AMI, heart failure, non-acute ischaemic heart disease and stroke                                                                                                                                                                                           12 (age, TC/HDL, diabetes duration, HbAIc, BMI, SBP and diastolic BP, history of events before diagnosis, LDL cholesterol, albuminuria, smoking status, BMI and gender)                                                                                                                                     Male : mean age, 55.36±9.28 years;\   Both male and female   993/21 775 (first stroke); 314/21 775 (second stroke)                                         82 232 person-years for first stroke and 4127 person-years for second stroke   Weibull proportional hazard model                               HL χ^2^ statistic: 11.22 (p=0.19) (first stroke); 8.09 (p=0.43) (second stroke)                                                              C-statistic=0.80 (0.78 to 0.82) (first stroke); C-statistic=0.74 (0.71 to 0.77) (second stroke)                                      No
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Female: mean age, 57.15±9.55 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Li *et al* [@R49]                    Taiwan             Ischaemic stroke                                                                                                                                                                                                                                                                       14 (age, gender, smoking habit, duration of type 2 diabetes, blood pressure, HbA1c level, total cholesterol to HDL ratio, creatinine, fasting plasma glucose variation, arterial embolism and thrombosis, diabetes retinopathy, hypoglycaemia, antidiabetes medication use and cardiovascular medication)   30--84 years                          Both male and female   2091 (derivation set), 1076 (validation set)/18 750 (derivation set), 9374 (validation set)   Mean follow-up of 8 years                                                      Cox proportional hazard regression model                        NR                                                                                                                                           AUROC=0.72 (3 years); AUROC=0.71 (5 years); AUROC=0.68 (8 years)                                                                     No

  Basu *et al* RECODe[@R36]            USA and Canada     Microvascular: nephropathy, retinopathy, neuropathy; Cardiovascular: composite of atherosclerotic cardiovascular disease (first fatal or non-fatal MI or stroke), fatal or non-fatal MI, fatal or non-fatal stroke, congestive heart failure, or death from any cardiovascular cause   14 (Age, sex, ethnicity, smoking, SBP, history of CVD, blood pressure-lowering drugs use, statin use, anticoagulants use, HbA1c, total cholesterol, HDL cholesterol, serum creatinine, urine ACR)                                                                                                           40--79 years                          Both male and female   197 (stroke)/9635                                                                             Median follow-up of 4.7 years                                                  Cox proportional hazard models                                  Calibration slope=1.16, χ^2^=7.4, p value=0.38 (internal validation); calibration slope=0.99, χ^2^=8.2, p value=0.22 (external validation)   C-statistic for stroke=0.70 (0.66 to 0.74) (internal validation); C-statistic for stroke=0.67 (0.63 to 0.71) (external validation)   Yes
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACR, albumin-to-creatinine ratio; AMI, acute myocardial infarction; AUROC, area under the receiver operating characteristic curve; BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CVD, cardiovascular disease; HDL, high-density lipoprotein; HL, Hosmer-Lemeshow; HbA1C, haemoglobin A1C; IRS, inflammatory risk score; JJ, The JDCS/J-EDIT; LDL, low-density lipoprotein; MI, myocardial infarction; NR, not reported; RECODe, Risk Equations for Complications of Type 2 Diabetes; SBP, systolic blood pressure; TC, total cholesterol; UKPDS, United Kingdom Prospective Diabetes Study.

A set of nine criteria was used to assess the quality of the studies and was summarised in [table 2](#T2){ref-type="table"}. All the studies specified inclusion/exclusion criteria. Non-biased selection of study participants was clear in all studies except the study by Palmer *et al*.[@R23] Handling of missing values was reported in four (44%) studies, modelling assumptions was satisfied by two studies and model external validation was performed in two studies. Stevens *et al* was the only study to mention whether the outcome was assessed without knowledge of the candidate predictors.[@R24] Duration of follow-up was long (≥5 years) in six models (67%). The clinical utility of the models was discussed in six (67%) studies and almost all studies reported their study limitations.

###### 

Study quality assessment of prediction models when outcome and corresponding performance measure (C-statistic) were reported for stroke

  Study                                   Inclusion/exclusion criteria specified   Non-biased selection   Missing value/loss to follow-up considered   Modelling assumptions satisfied   Model external validation   Outcome assessed without knowledge of the candidate predictors (ie, blinded)   Duration of follow-up long enough   Potential clinical use of the model discussed   Study limitations discussed
  --------------------------------------- ---------------------------------------- ---------------------- -------------------------------------------- --------------------------------- --------------------------- ------------------------------------------------------------------------------ ----------------------------------- ----------------------------------------------- -----------------------------
  Yang *et al* [@R38]                     Yes                                      Yes                    Not clear                                    No                                No                          Not clear                                                                      Yes                                 Yes                                             Yes
  Kothari *et al* [@R21]                  Yes                                      Yes                    No                                           Yes                               Yes                         Not clear                                                                      Yes                                 Yes                                             Yes
  Wells *et al* [@R47]                    Yes                                      Yes                    Yes                                          No                                No                          Not clear                                                                      No                                  Yes                                             Yes
  Stevens *et al* (UKPDS 66)[@R24]        Yes                                      Yes                    Not clear                                    No                                No                          Yes                                                                            Yes                                 Yes                                             No
  Tanaka *et al* (JJ Risk Engine)[@R48]   Yes                                      Yes                    Yes                                          No                                No                          Not clear                                                                      Yes                                 No                                              Yes
  Palmer *et al* (IRS)[@R23]              Yes                                      Not clear              No                                           No                                No                          Not clear                                                                      Yes                                 No                                              Yes
  Kiadaliri *et al* [@R22]                Yes                                      Yes                    Yes                                          No                                No                          Not clear                                                                      No                                  No                                              Yes
  Li *et al* [@R49]                       Yes                                      Yes                    Yes                                          Yes                               No                          Not clear                                                                      Yes                                 Yes                                             Yes
  Basu *et al* RECODe[@R36]               Yes                                      Yes                    No                                           Not clear                         Yes                         Not clear                                                                      No                                  Yes                                             Yes

IRS, inflammatory risk score; JJ, The JDCS/J-EDIT; RECODe, Risk Equations for Complications of Type 2 Diabetes; UKPDS, United Kingdom Prospective Diabetes Study.

Predicting risk of stroke (as part of a composite CVD outcome) in populations with diabetes {#s3-2}
-------------------------------------------------------------------------------------------

We identified 23 models developed in diabetes populations that reported their outcome as a composite of CVD. A summary of the characteristics of these prediction models is described in [table 3](#T3){ref-type="table"}. The number of participants considered in the model development ranged from 132 to 1 81 619 with an average age of \>50 years. Duration of follow-up (mean, median, maximum) ranged from 11 months to 11.8 years with 14 models with ≥5 years and nine models with \<5 years of follow-up. The number of predictors included in prediction models ranged from 4 to 18 with an average of 11 predictors per model. The most common predictors included in the models were age, sex, systolic blood pressure and HbA1c, smoking and high-density lipoprotein-cholesterol. Four models were externally validated after its development and 17 of them had never been validated in an external population. Calibration of the prediction models was reported by 13 studies while discrimination reported by almost all studies with C-statistics ranging from 0.60 to 0.92. The median C-statistic of the models was 0.70 with a large amount of unexplained heterogeneity in the discriminative performance of these models (I^2^=93.7%; Cochran Q-statistic p\<0.001; [figure 3](#F3){ref-type="fig"}). Sample size (small vs large, p=0.46), models' external validation (externally validated vs not externally validated, p=0.71), variables included in the model (few vs many, p=0.21) and geographic location (Europe vs others, p=0.08) were not identified as significant sources of heterogeneity in the discriminative performance of these models. The discriminative ability of the model by Ofstad *et al* [@R25] was highest (C-statistic=0.92) when novel risk markers were added to their standard model. The funnel plot and Begg's test (p=0.24) suggested the absence of small study effects, with no correlation between studies of smaller cohorts reporting higher C-statistics ([online supplemental figure S2](#SP1){ref-type="supplementary-material"}). Only four models were developed using logistic regression models while others were developed mostly using Cox proportional hazards models.

![Forest plot of C-statistics, with 95% CIs of risk prediction models when stroke was reported as part of a composite cardiovascular disease outcome. AD-ON, Action in Diabetes and Vascular Disease:Preterax and Diamicron Modified Release Controlled Evaluation-Observational; EPIC-NL,European Prospective Investigation into Cancer and Nutrition-Netherlands; HWNNs,hybrid wavelet neural networks; MACE, major adverse cardiovascular event; NZDCS, New Zealand Diabetes Cohort Study; SMART, second manifestations ofarterial disease; SOMs, self-organising maps.](bmjopen-2018-025579f03){#F3}

###### 

Characteristics of prediction models when stroke is reported as a part of composite CV outcome and performance measure (C-statistic) is presented for the composite CV outcome

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                         Location                                                        Outcome                                                                                                                                                                                    No of predictors                                                                                                                                                                                                                                                                                               Age                                                       Gender                 Events (n)/total participants (N)                        Duration of follow-up                                                                                                              Modelling Method                              Calibration                                                                                                                                                 Discrimination (with CI)                                                                                                                                                                       External Validation
  --------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ---------------------- -------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  Brownrigg *et al* [@R15]                      England                                                         CVD events (non-fatal MI, coronary revascularisation, congestive cardiac failure, transient ischaemic attack and stroke)                                                                   6 (age, sBP, smoking status, LDL-C and HDL-C and peripheral neuropathy)                                                                                                                                                                                                                                        Mean age of 63.8 years                                    Both male and female   399/13 043                                               Total 2.5 years                                                                                                                    Probability weighted Cox regression           χ^2^=121.2, p\<0.001                                                                                                                                        C-statistic=0.661 (0.636 to 0.686) (with PN)                                                                                                                                                   No

  Khalili *et al* [@R50]                         Iran                                                           CVD events (deﬁnite MI, probable MI, unstable angina, angiographic-proven CHD, stroke, death from CVD)                                                                                     4 (BMI, waist circumference, WHR, and waist-to-height ratio)                                                                                                                                                                                                                                                   Mean age 55.7 years (male), 52.7 years (female)           Both male and female   188/1010                                                 Median follow-up 8.4 years                                                                                                         Cox proportional hazard model                 NR                                                                                                                                                          C-statistic=0.64 (0.58 to 0.70) (for diabetic men with WHR, model 2) and C-statistic=0.70 (0.65 to 0.75) (for diabetic women with WHR, model 2)                                                No

  Cederholm *et al* [@R51]                      Sweden                                                          Fatal or non-fatal CVD (CHD or stroke, whichever came first)                                                                                                                               9 (A1C, age at the onset of diabetes, diabetes duration, sex, BMI, smoking, sBP, antihypertensive drugs and lipid-reducing drugs)                                                                                                                                                                              18--70 years                                              Both male and female   1482/11 646                                              Mean follow-up 5.64 years                                                                                                          Cox regression                                HL test: χ^2^=4.29 (p=0.83) and the ratio of observed to predicted survival rates=0.999. Excellent calibration                                              C-statistic=0.70                                                                                                                                                                               No

  Davis *et al* [@R33]                          Australia                                                       CVD (hospitalisation for/with MI or stroke, and death from cardiac or cerebrovascular causes or sudden death)                                                                              7 (age, sex, prior CVD, ln (urinary albumin : creatinine ratio), lnHbA1c, ln(HDL-C), Southern European ethnic background and aboriginality)                                                                                                                                                                    Mean age 64.1 (38.7--83.7) years                          Both male and female   185/1240                                                 Mean follow-up 4.5 years                                                                                                           Cox proportional hazards model                 HLˆC test, p=0.74                                                                                                                                          AUC=0.80, p\<0.001                                                                                                                                                                             Yes

  Kengne *et al* [@R34]                         20 Countries (Asia, Australasia, Europe and Canada)             CVD (fatal or non-fatal MI or stroke or CV death)                                                                                                                                          10 (age at diagnosis, known duration of diabetes, sex, pulse pressure, treated hypertension, atrial fibrillation, retinopathy, HbA1c, log of urinary albumin/creatinine ratio and non-HDL-C at baseline)                                                                                                       Mean age 65.8 (6.3) years                                 Both male and female   473/7168                                                 4.5 years                                                                                                                          Cox regression model                          HL test: p=0.76 (ADVANCE cohort)                                                                                                                            AUC=0.702 (0.676 to 0.728) (ADVANCE cohort)                                                                                                                                                    Yes

  Ofstad *et al* [@R25]                         Norway                                                          Death or first CV event (MI, stroke or hospitalisation for unstable angina pectoris)                                                                                                       11 (age, gender, known CVD, dB, microalbuminuria, serum levels of HDL-C and creatinine); novel risk markers: (IL-6, log Activin A, E/Em, pathol recovery loop)                                                                                                                                                 Mean age 58.5±10.0 (SD) years                             Both male and female   36/132                                                   8.6±2.1 years                                                                                                                      Cox proportional hazard model                 NR                                                                                                                                                          C-statistic: STD model: 0.794; STD + IL-6 model: 0.913; STD + log Activin A model: 0.859;\                                                                                                     No
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 STD + IL-6 + log Activin A model: 0.923;\                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 STD + E/Em + pathol recovery loop model: 0.891                                                                                                                                                 

  Looker *et al* [@R52]                         Five cohorts from Europe                                        CVD (acute CHD or an ischaemic stroke)                                                                                                                                                     14 (age, sex, smoking, sBP and dBP, LDL-C, HDL-C, triacylglycerol, diabetes duration, HbA1C, BMI, height,\                                                                                                                                                                                                     Median age 68.4 years (controls) and 68.8 years (cases)   Both male and female   1123/2310                                                Median follow-up 3.2 years for cases and 6.5 years for controls                                                                    Forward selection using logistic regression   NR                                                                                                                                                          AUROC=0.72 (full clinical covariate set plus forward selection biomarkers)                                                                                                                     No
                                                                                                                                                                                                                                                                                                           (eGFR), cohort and current medication (including antihypertensive agents, aspirin, lipid-lowering agents and insulin therapy)).\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                           +6 Biomarkers (NT-proBNP apoCIII hsTnT IL-6 sRAGE IL-15)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Mukamal *et al* [@R32]                        USA                                                             MI, stroke, CV death                                                                                                                                                                       7 in basic model (Age, smoking, sBP, total and HDL-C, creatinine and the use of glucose-lowering agents)                                                                                                                                                                                                       Mean age 72.6 years for female and 73.0 years for male    Both male and female   265/782                                                  10 years                                                                                                                           Cox proportional hazard model                 Basic model: HL p=0.25; basic model+CRP: HL p=0.87; Basic Model+CRP + (ABI, internal carotid wall thickness, ECG left ventricular hypertrophy): HL p=0.65   Basic model: C -statistic=0.64; Basic model+CRP: C- statistic=0.64; Basic model+CRP + (ABI, internal carotid wall thickness, ECG left ventricular hypertrophy): C-statistic=0.68               Yes

  Paynter *et al* [@R53]                        USA                                                             MI, ischaemic stroke, coronary revascularisation or CV death                                                                                                                               8 in different models (age, sBP, total cholesterol, HDL-C, smoking, CRP, parental history of premature MI and HbA1c)                                                                                                                                                                                           Median age 55 years for female and 67.8 years for male    Both male and female   125/685 (women); 170/563 (men)                           Median follow-up 10.2 years (women); median follow-up 11.8 years (men)                                                             Cox proportional hazards model                NR                                                                                                                                                          C-statistic of model with HbA1c=0.692 (ATP III) and=0.697 (RRS) for women; C-statistic of model with HbA1c=0.602 (ATP III) and=0.605 (RRS) for men.                                            No

  Price *et al* [@R54]                          Scotland                                                        All CV events (fatal and non-fatal MI, angina, fatal IHD, fatal and non-fatal stroke and TIA)                                                                                              18 (age, sex, baseline CVD status, duration, diabetes treatment, lipid-lowering drugs, BP-lowering drugs, smoking status, BMI, sBP, dBP, HbA1c, HDL-C, total cholesterol, eGFR, microalbuminuria and social status +NT-proBNP) (model D)                                                                       60--75 years                                              Both male and female   112/1066                                                 4 years                                                                                                                            Cox proportional hazards model                NR                                                                                                                                                          C-statistic=0.748 (0.691 to 0.805) (model D)                                                                                                                                                   No

  Selby *et al* [@R55]                          USA                                                             Macrovascular and microvascular complications (MI, other ischaemic heart disease, congestive heart failure, cerebrovascular accident, etc)                                                 16 (outpatient diagnoses, inpatient events, age, antihypertensives, serum creatinine, diabetes treatment, mean HbA1c, albuminuria, primary care visits, outpatient diagnoses of obesity, outpatient ID diagnoses, mean total cholesterol, self-report of neuropathy, education, type of diabetes, sex)         Mean age of 60.8 years                                    Both male and female   1997/28 838                                              1 year                                                                                                                             Logistic regression model                     NR                                                                                                                                                          AUC=0.64 (full model)                                                                                                                                                                          No

  Zethelius *et al* [@R35]                      Sweden                                                          Fatal/non-fatal CVD (the composite of CHD or stroke)                                                                                                                                       12 (onset age of diabetes, diabetes duration, total-cholesterol-to-HDL-C ratio, HbA1c, sBP, BMI, males sex, smoker, microalbuminuria, macroalbuminuria, atrial fibrillation, previous CVD)                                                                                                                     30--74 years                                              Both male and female   2488/24 288                                              Mean follow-up of 4.8 years                                                                                                        Cox proportional hazard model                 Modified HL χ^2^ statistic=0.13 (p=0.9)                                                                                                                     C-statistic=0.71                                                                                                                                                                               No

  Alrawahi *et al* [@R41]                       Oman                                                            First fatal or non-fatal CHD, stroke, or PAD                                                                                                                                               7 (age, diabetes duration, HbA1c, total cholesterol, albuminuria, hypertension, BMI)                                                                                                                                                                                                                           54.5±11.4 years                                           Both male and female   192/2039                                                 Mean follow-up of 5.3 years                                                                                                        Cox regression model                          NR                                                                                                                                                          NR                                                                                                                                                                                             No

  Zarkogianni *et al* [@R56]                    Greece                                                          Fatal or non-fatal CVD: stroke and CHD                                                                                                                                                     16 (age, diabetes duration, BMI, glycosylated haemoglobin, pulse pressure, fasting glucose, total cholesterol, triglycerides, HDL-C, smoking habit, sex, hypertension, lipid-lowering therapy, aspirin, insulin therapy, parental history of diabetes)                                                         58.56±10.70 years                                         Both male and female   41/560                                                   5-year follow-up                                                                                                                   Machine learning: HWNNs and SOMs              Brier score: 0.08±0.01 (HWNN-based ensemble 4); 0.07±0.01 (SOM-based ensemble 4); 0.007±0.02 (hybrid ensemble)                                              AUC=0.6764±0.1509 (HWNN-based ensemble 4); AUC=0.7054±0.1372 (SOM-based ensemble 4); AUC=0.7148±0.1573 (hybrid ensemble)                                                                       No

  Price *et al* [@R57]                          Scotland                                                        Fatal or non-fatal MI or stroke, angina, fatal IHD, TIA, coronary intervention                                                                                                             13 (age, sex, smoking, atrial fibrillation, CKD, arthritis, hypertension, BMI, SBP, total HDL-C, social status, baseline CVD status, lipid-lowering medication) in basic model + (ABI, hs-cTnT, GGT, proBNP, g) in full model                                                                                  60--75 years                                              Both male and female   205/1066                                                 8 years                                                                                                                            Binary logistic regression                    HL p=0.97 (basic model); HL p=0.39 (full model). Well calibrated                                                                                            C-statistic=0.722 (0.681 to 0.763) (basic model); C-statistic=0.74 (0.699 to 0.781) (full model)                                                                                               No

  Wan *et al* [@R58]                            China                                                           IHD, MI, coronary death and sudden death, heart failure, fatal and non-fatal stroke                                                                                                        13 (age, eGFR, total cholesterol/HDL-C ratio, urine ACR, smoker, duration of diabetes mellitus, sBP, HbA1c, anti-hypertensive drugs used, dBP, BMI, insulin used, anti-glucose oral drugs used)                                                                                                                18--79 years                                              Both male and female   Events (n) NR/137 935                                    Median follow-up of 5 years                                                                                                        Cox proportional hazard regression            Calibration plots: good calibration                                                                                                                         Harrell's C-statistic Male: 0.705 (0.693 to 0.716) (model 1), 0.689 (0.678 to 0.701) (model 2); Female: 0.719 (0.707 to 0.731)(model 1), 0.708 (0.696 to 0.719) (model 2)                      No

  Young *et al* [@R59]                          USA                                                             MACE: non-fatal MI, non-fatal stroke and CVD-related death; MACE-plus: any MACE, hospitalisation for unstable angina, or hospitalisation for congestive heart failure; CVD-related death   12 (age, gender, type of insurance, race, region, diabetes-related hospitalisations, prior CVD diagnoses, chronic pulmonary disease, use of antihypertensive drugs, use of antihyperglycaemic drugs, HbA1c, urine ACR)                                                                                         50 years or older                                         Both male and female   13 856 (MACE), 20 100 (MACE-plus)/181 619                Median duration of the at-risk period: 12 months (primary prevention population) and 11 months (secondary prevention population)   Logistic regression                           NR                                                                                                                                                          C-statistic=0.70 (MACE); C-statistic=0.72 (MACE-plus); C-statistic=0.77 (CVD-related death)                                                                                                    No

  van der Leeuw *et al* [@R60]                  The Netherlands                                                 Major CV events (MI, stroke and vascular death)                                                                                                                                            12 (age at diabetes diagnosis, duration of diagnosed diabetes, sex, smoking, HbA1c, sBP, total cholesterol/\                                                                                                                                                                                                   Mean age 59±10 years (SMART), 58±7 (EPIC-NL)              Both male and female   248 (SMART), 134 (EPIC-NL)/1002 (SMART), 218 (EPIC-NL)   Median follow-up 9.2 years in SMART and 11.3 years in EPIC-NL                                                                      Cox proportional hazard model                 Calibration plots                                                                                                                                           Base model: C-statistic=0.70 (0.67 to 0.74) (SMART), C-statistic=0.69 (0.64 to 0.74) (EPIC-NL); Multimarker model: C-statistic=0.73 (0.68 to 0.79) (SMART), C-statistic=0.72 (0.64 to 0.77)\   No
                                                                                                                                                                                                                                                                                                           HDL-C ratio, previous\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                (EPIC-NL)                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                           CV event, urinary ACR or eGFR) in base model+NT-proBNP, osteopontin, and MMP-3 in multimarker model                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Alshehry *et al* [@R61]                       20 countries from Asia, Australasia, Europe and North America   Non-fatal MI, non-fatal stroke, and CV death                                                                                                                                               14 (age, sex, BMI, SBP, glycohaemoglobin, HDL-C, eGFR, diabetes duration, CRP, history of macrovascular disease, history of heart failure, use of antihypertensive medication, use of antiplatelet medication, exercise) in base model + 7 lipid species                                                       Mean age 67 years                                         Both male and female   698/3779                                                 Median follow-up of 5 years                                                                                                        Weighted Cox regression                       NR                                                                                                                                                          Base model: C-statistic=0.68 (0.678 to 0.682); base model + 7 lipid species: C-statistic=0.70 (0.698 to 0.702)                                                                                 No

  Woodward *et al* The AD-ON Risk Score[@R62]   20 countries from Asia, Australasia, Europe and North America   Non-fatal MI, non-fatal stroke or death from any CV cause, renal death or requirement for renal replacement therapy or renal transplantation                                               13 (age, sex, sBP with and without use of antihypertensives, duration of diabetes, HbA1c, urinary ACR, eGFR and its square, age at completion of formal education, exercise, history of diabetic retinopathy and current or previous atrial fibrillation)                                                      Mean age of 65.8 years                                    Both male and female   1145/7301                                                Median follow-up of 9.9 years                                                                                                      Cox regression model                          Calibration plots and HL test (p=0.13). Excellent calibration                                                                                               C-statistic=0.668 (0.651 to 0.685)                                                                                                                                                             No

  Parrinello *et al* [@R63]                     USA                                                             Incident CHD, stroke, heart failure, CKD, lower extremity amputation or peripheral vascular bypass                                                                                         18 (age, sex, race, education, smoking status, alcohol consumption, physical activity, family history of CVD, glucose-lowering medication use, antihypertensive medication use, cholesterol-lowering medication use, recent onset of diabetes, BMI, LDL-C, HDL-C, triglycerides, sBP, HbA1c) + 12 biomarkers   Mean age of 58.1 years                                    Both male and female   141 (CVD events)/654                                     Maximum follow-up of 10 years                                                                                                      Fine and Gray model                           Calibration plots: well calibrated                                                                                                                          C-statistic=0.667 (0.64 to 0.70) (model 1); C-statistic=0.683 (0.65 to 0.71) (model 2); C-statistic=0.694 (0.66 to 0.72) (model 3); C-statistic=0.716 (0.69 to 0.74) (model 4)                 No

  Colombo *et al* [@R64]                        UK and Ireland                                                  Acute CHD (MI, unstable angina, revascularisation or acute CHD death), fatal or non-fatal stroke                                                                                           8 (age, sex, SBP, total cholesterol, HDL-C, smoking status, apoCIII and NT-proBNP)                                                                                                                                                                                                                             Median age of 62.9 years                                  Both male and female   144/2105                                                 Maximum follow-up of 5 years                                                                                                       Cox proportional hazard model                 NR                                                                                                                                                          AUROC=0.661 (0.615 to 0.706) (Framingham covariates alone); AUROC=0.745 (0.701 to 0.789) (full model with additional biomarkers)                                                               No

  Elley *et al* NZ DCS[@R40]                    New Zealand                                                     Fatal or non-fatal CVD event (ischaemic heart disease, cerebrovascular accident/transient ischaemic attack, PAD)                                                                           9 (age at diagnosis, diabetes duration, sex, sBP, smoking status, total cholesterol: HDL ratio, ethnicity, glycated HbA1C), urine ACR)                                                                                                                                                                         Median age of 59 years                                    Both male and female   6479/36 127                                              Median follow-up of 3.9 years                                                                                                      Cox proportional hazards regression models    Calibration plot                                                                                                                                            AUROC=0.68 (0.67 to 0.70) (CVD)                                                                                                                                                                Yes
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ABI, ankle--brachial index; AD-ON, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation-Observational;ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation; apoCIII, Apolipoprotein C-III; ATP, Adult Treatment Panel; AUC, area under the curve; AUROC, area under the receiver operating characteristic curve; BMI, body mass index; CHD, coronary heart disease; CKD, chronic kidney disease; CRP, C reactive protein; CV, cardiovascular; CVD, cardiovascular disease; dBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; EPIC-NL, European Prospective Investigation into Cancer and Nurition Netherlands;GGT, gamma-glutamyl transferase; HbA1C, haemoglobin A1C; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; HL, Hosmer-Lemeshow; HL^∧^C, Hosmer-Lemeshow C-test;hs-cTnT, high-sensitivity cardiac troponin T; HWNNs, hybrid wavelet neural networks; ID, infectious disease; IHD, ischaemic heart disease;IL-6, interleukin 6; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event; MI, myocardial infarction;MMP-3, matrix metalloproteinase-3; NR, not reported;NT-proBNP, N-terminal pro b-type Natriuretic Peptide; NZ DCS, New Zealand Diabetes Cohort Study; PAD, peripheral artery disease; PN, peripheral neuropathy; RRS, Reynolds risk score; sBP, systolic blood pressure; SMART, second manifestations of arterial disease; SOMs, self-organising maps; STD, standard; TIA, transient ischaemic attack; WHR, waist-to-hip ratio.

The study quality for this group of models is summarised in [table 4](#T4){ref-type="table"}. Similar to the models developed in diabetic populations that look at the outcome of stroke specifically, we found that study quality was similar.

###### 

Study quality assessment of prediction models when stroke is reported as a part of composite CV outcome and performance measure (C-statistic) is presented for the composite CV outcome

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                          Inclusion/ exclusion criteria specified   Non-biased selection   Missing value/loss to follow-up considered   Modelling assumptions satisfied   Model external validation   Outcome assessed without knowledge of the candidate predictors (ie, blinded)   Duration of follow-up long enough   Potential clinical use of the model discussed   Study limitations discussed
  ---------------------------------------------- ----------------------------------------- ---------------------- -------------------------------------------- --------------------------------- --------------------------- ------------------------------------------------------------------------------ ----------------------------------- ----------------------------------------------- -----------------------------
  Brownrigg *et al*.[@R15]                       Yes                                       No                     No                                           No                                No                          Not clear                                                                      No                                  Yes                                             Yes

   Khalili *et al* [@R50]                        Yes                                       No                     No                                           Yes                               No                          Not clear                                                                      Yes                                 Yes                                             Yes

  Cederholm *et al* [@R51]                       Yes                                       Not clear              No                                           Yes                               No                          Not clear                                                                      Yes                                 Yes                                             Yes

  Davis *et al*\                                 Not clear                                 Not clear              No                                           Yes                               Yes                         Not clear                                                                      No                                  No                                              No
  [@R33]                                                                                                                                                                                                                                                                                                                                                                                        

  Kengne *et al* [@R34]                          Yes                                       Yes                    Not clear                                    Not clear                         Yes                         Not clear                                                                      No                                  Yes                                             Yes

  Ofstad *et al* [@R25]                          Yes                                       Not clear              Yes                                          Yes                               No                          Not clear                                                                      Yes                                 Yes                                             Yes

  Looker *et al* [@R52]                          Yes                                       Not clear              Yes                                          Not Clear                         No                          Not clear                                                                      No                                  Yes                                             Yes

  Mukamal *et al* [@R32]                         Yes                                       Yes                    Yes                                          Yes                               Yes                         Not Clear                                                                      Yes                                 Yes                                             Yes

  Paynter *et al* [@R53]                         Yes                                       Yes                    No                                           No                                No                          Not Clear                                                                      Yes                                 No                                              No

  Price *et al*\                                 Yes                                       Not clear              Not clear                                    No                                No                          Not clear                                                                      No                                  No                                              Yes
  [@R54]                                                                                                                                                                                                                                                                                                                                                                                        

  Selby *et al*\                                 Yes                                       Yes                    Yes                                          No                                No                          Not clear                                                                      No                                  Yes                                             Yes
  [@R55]                                                                                                                                                                                                                                                                                                                                                                                        

  Zethelius *et al* [@R35]                       Yes                                       Not clear              No                                           Yes                               No                          Not clear                                                                      No                                  Yes                                             Yes

  Alrawahi *et al* [@R41]                        Yes                                       Yes                    No                                           Yes                               No                          Not clear                                                                      Yes                                 Yes                                             Yes

  Zarkogianni *et al* [@R56]                     No                                        Not clear              Not clear                                    Yes                               No                          Not clear                                                                      Yes                                 Yes                                             Yes

  Price *et al* [@R57]                           Not clear                                 Yes                    No                                           Not clear                         No                          Not clear                                                                      Yes                                 Yes                                             Yes

  Wan *et al* [@R58]                             Yes                                       Yes                    Yes                                          Yes                               No                          Not clear                                                                      Yes                                 Yes                                             Yes

  Young *et al* [@R59]                           Yes                                       Yes                    Not clear                                    Not clear                         No                          Not clear                                                                      Not clear                           Yes                                             Yes

  van der Leeuw *et al* [@R60]                   Yes                                       Not clear              Yes                                          Not clear                         No                          Not clear                                                                      Yes                                 Yes                                             Yes

  Alshehry *et al* [@R61]                        Yes                                       Yes                    Not clear                                    Not clear                         No                          Not clear                                                                      Yes                                 Yes                                             Yes

  Woodward *et al*. The AD-ON Risk Score[@R62]   Yes                                       Yes                    Not clear                                    Not clear                         No                          Not clear                                                                      Yes                                 Yes                                             Yes

  Parrinello *et al* [@R63]                      Yes                                       Yes                    No                                           Not clear                         No                          Not clear                                                                      Yes                                 Yes                                             Yes

  Colombo *et al* [@R64]                         Yes                                       Yes                    Yes                                          Not clear                         No                          Not clear                                                                      No                                  Yes                                             Yes

  Elley *et al*. NZ DCS[@R40]                    Yes                                       Not clear              Yes                                          Yes                               Yes                         Not clear                                                                      No                                  Yes                                             No
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD-ON, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation-Observational; NZ DCS, New Zealand Diabetes Cohort Study.

Validation studies of stroke prediction models developed in populations with and without diabetes {#s3-3}
-------------------------------------------------------------------------------------------------

Seventeen risk prediction models for stroke (developed both in patients with diabetes and in general populations) were validated in diabetes populations by 33 studies ([table 5](#T5){ref-type="table"}). Among the 17 validated models, 14 of them were externally validated in independent cohorts and 3 of them were internally validated in a test sample or separate data set from the same cohort. Three studies validated more than one risk model in the same cohort. Models with multiple validations (two or more) and reported C-statistics are provided in [figure 4](#F4){ref-type="fig"}. Models that had only been validated once were excluded from meta-analysis. In addition, only those studies that provided enough information to estimate the variance of the provided C-statistic for meta-analysis were considered for analysis.

![Forest plot of C-statistics, with 95% CIs, of stroke prediction models that are externally validated in two or more independent cohorts. JHS, Jackson Heart Study; MESA,Multiethnic Study of Atherosclerosis; UKPDS, United Kingdom ProspectiveDiabetes Study](bmjopen-2018-025579f04){#F4}

###### 

Characteristics of the validation studies of the stroke prediction models

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study name                                                       No of Studies                     Validation study                                                                      Location                                                         Outcome                                                                                                                                                                                                                                        Age                                                                                    Gender                     Events (n) /total participants (N)                                                                                                                                                                               Calibration                                                                                                           Discrimination (with CI)
  ---------------------------------------------------------------- --------------------------------- ------------------------------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- -------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Kothari *et al*, UKPDS Risk Engine for Stroke (UKPDS 60)[@R21]   12                                Kengne *et al* [@R31]                                                                 20 Countries (Australasia, Asia,\                                Major CHD, major CVD and major cerebrovascular event (death from cerebrovascular disease and non-fatal stroke)                                                                                                                                 Mean age 66 years for both males and females                                           Both male and female       288/7502                                                                                                                                                                                                         HL χ^2^=138.7 (p\<0.0001) (major event); HL χ^2^=114.3 (p\<0.0001) (any event)                                        AUC=0.62 (major event); AUC=0.61 (any event)
                                                                                                                                                                                           Europe, North America)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                     Davis *et al* [@R65]                                                                  Australia                                                        Fatal stroke, all stroke                                                                                                                                                                                                                       Mean age of 62.2 years                                                                 Both male and female       13 (fatal stroke), 23 (all stroke)/791                                                                                                                                                                           HL∧C-test: p=0.06 (fatal stroke) and p=0.33 (all stroke), good calibration                                            AUC=0.88 (0.81 to 0.96) (fatal stroke); AUC=0.86 (0.78 to 0.93) (all stroke)

                                                                                                     Kothari *et al* [@R21]                                                                UK                                                               Fatal stroke                                                                                                                                                                                                                                   Mean age 51.5 years for males and 52.6 years for females.                              Both male and female       197/1370                                                                                                                                                                                                         NR                                                                                                                    NR

                                                                                                     Jiao *et al* [@R66]                                                                   Hong Kong                                                        Stroke                                                                                                                                                                                                                                         Mean age 64.3 years (RAMP-DM) and 65.3 years (control)                                 Both male and female       Total CVD events n=10 (RAMP-DM) and n=13 (control group) /RAMP-DM group n=1072, control group n=1072                                                                                                             NR                                                                                                                    NR

                                                                                                     Yang *et al* [@R38]                                                                   Hong Kong, China                                                 Stroke                                                                                                                                                                                                                                         Median age 57 years                                                                    Both male and female       182/3541                                                                                                                                                                                                         NR                                                                                                                    Unadjusted AUROC=0.588 (0.549 to 0.626)

                                                                                                     Lahoz-Rallo *et al* [@R67]                                                            Spain                                                            Cerebrovascular risk (stroke)                                                                                                                                                                                                                  Mean age 65.5 years                                                                    Both male and female       Events (n) NR/ n=1846                                                                                                                                                                                            NR                                                                                                                    NR

                                                                                                     Metcalf *et al* [@R68]                                                                New Zealand                                                      Stroke                                                                                                                                                                                                                                         35 to 74 years                                                                         Both male and female       Events (n) NR/n=423                                                                                                                                                                                              NR                                                                                                                    NR

                                                                                                     Tanaka *et al* [@R48]                                                                 Japan                                                            Stroke                                                                                                                                                                                                                                         40 to 84 years                                                                         Both male and female       89/1748                                                                                                                                                                                                          HL test: (p=0.54)                                                                                                     C-statistic=0.638 (0.566 to 0.7 11)

                                                                                                     Wells *et al* [@R47]                                                                  USA                                                              Stroke                                                                                                                                                                                                                                         18 years of age or older                                                               Both male and female       Events (n): stroke (1088)/total participants (N): stroke (26 140)                                                                                                                                                Risk underestimated when examining calibration in the large                                                           C- statistic=0.752

  Bannister *et al* [@R69]                                         UK                                CHD, fatal CHD, stroke, fatal stroke                                                  Mean age 60.3 years (male) and 62.6 years (female)               Both male and female                                                                                                                                                                                                                           6717/79 966 (stroke), 7037/79 966 (fatal stroke)                                       NR                         C-statistic=0.73 (0.72 to 0.75) (stroke, female), C-statistic=0.71 (0.70 to 0.72) (Stroke, male); C-statistic=0.77(0.74 to 0.80) (fatal stroke, female), C-statistic=0.78 (0.76 to 0.81\] (fatal stroke, male)                                                                                                                         

                                                                                                     Wu *et al* [@R70]                                                                     China                                                            Stroke and CHD                                                                                                                                                                                                                                 20 years and above                                                                     Both male and female       Events (n) NR/n=1584                                                                                                                                                                                             NR                                                                                                                    NR

                                                                                                     Ipadeola *et al* [@R71]                                                               Nigeria                                                          CHD and stroke                                                                                                                                                                                                                                 Mean age 60.5±9.89 years                                                               Both male and female       Events (n) NR/340                                                                                                                                                                                                NR                                                                                                                    NR

  Clarke *et al*, UKPDS Outcomes Model[@R27]                       4                                 Leal *et al* [@R72]                                                                   UK                                                               MI/stroke/IHD/heart failure/amputation/blindness/renal failure/death from any cause                                                                                                                                                            Mean age 62 years                                                                      Both male and female       Events (n) NR/n=4031                                                                                                                                                                                             Calibration plots: overestimated                                                                                      C-statistic=0.68 (0.65 to 0.71) (stroke)

  McEwan *et al* [@R73]                                            UK                                CHF/IHD/MI/stroke/blindness/ESRD/amputation                                           Mean age 51.49 years (low risk) and 66.08 years (intermediate)   Both male and female                                                                                                                                                                                                                           723 (stroke)/54 169 (all in low-risk patient)                                          NR                         ROC=0.62 (stroke)                                                                                                                                                                                                                                                                                                                      

  Pagano *et al* [@R74]                                            Italy                             MI, other IHD, stroke, CHF and amputation (2000 survey) and mortality (1991 survey)   Mean age 57.9 years (1991 survey) and 57.4 years (2000 survey)   Both male and female                                                                                                                                                                                                                           Events (n) NR/n=2514 (2000 survey) and n=1443 (1991 survey)                            NR                         NR                                                                                                                                                                                                                                                                                                                                     

  Tao *et al* [@R75]                                               UK, Denmark and the Netherlands   MI and stroke                                                                         40--69 years (50--69 years in the Netherlands)                   Both male and female                                                                                                                                                                                                                           Events (n) NR/2899                                                                     HL test: p=0.33 (Stroke)   AUROC=0.70 (0.64 to 0.77) (stroke)                                                                                                                                                                                                                                                                                                     

  Stevens *et al*, UKPDS Risk Engine (UKPDS 56)[@R26]              5                                 Shivakumar *et al* [@R76]                                                             India                                                            CHD and stroke                                                                                                                                                                                                                                 Mean age 63.3 years                                                                    Both male and female       NR                                                                                                                                                                                                               NR                                                                                                                    NR

                                                                                                     Moazzam *et al* [@R77]                                                                Pakistan                                                         CHD, fatal CHD, stroke, fatal stroke                                                                                                                                                                                                           30--74 years                                                                           Both male and female       Events (n) NR/470                                                                                                                                                                                                NR                                                                                                                    NR

                                                                                                     Ezenwaka *et al* [@R78]                                                               Trinidad and Tobago                                              Absolute CHD and stroke                                                                                                                                                                                                                        Mean age 63.1 years (male) and 59.5 years (female)                                     Both male and female       Events (n) NR/325                                                                                                                                                                                                NR                                                                                                                    NR

                                                                                                     Sun *et al* [@R79]                                                                    China                                                            CHD and stroke                                                                                                                                                                                                                                 21--94 years (58.4±12.9 years)                                                         Both male and female       Events (n) NR/853 (no of patients with CKD)                                                                                                                                                                      NR                                                                                                                    NR

                                                                                                     Pang *et al* [@R80]                                                                   China                                                            CHD and stroke                                                                                                                                                                                                                                 21--90 years                                                                           Both male and female       Events (n) NR/1178                                                                                                                                                                                               NR                                                                                                                    NR

  Anderson *et al*, (Framingham Risk Score)[@R28]                  2                                 Herder *et al* [@R81]                                                                 Germany                                                          MI, stroke, cardiovascular death                                                                                                                                                                                                               NR                                                                                     Both male and female       84/1072                                                                                                                                                                                                          Observed/expected events reported. Good calibration (p\>0.05) in all quintiles except quintile 4                      C-statistic=0.636

                                                                                                     Kengne *et al* [@R31]                                                                 20 countries (Australasia, Asia,\                                Major CHD, major CVD and major cerebrovascular event (death from cerebrovascular disease and non-fatal stroke)                                                                                                                                 Mean age 66 years for both male and female                                             Both male and female       288/7502                                                                                                                                                                                                         HL χ^2^=42.7 (p\<0.0001) (major event); HL χ^2^=149.0 (p\<0.0001) (any event)                                         AUC=0.568 (major event); AUC=0.555 (any event)
                                                                                                                                                                                           Europe, North America)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  D'Agostino *et al*,\                                             2                                 Ataoglu *et al* [@R30]                                                                Turkey                                                           Cardiovascular death, non-fatal MI, angina, ischaemic stroke                                                                                                                                                                                   NR                                                                                     Both male and female       66/102                                                                                                                                                                                                           NR                                                                                                                    NR
  (Framingham Risk Score)[@R29]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                     Kengne *et al* [@R31]                                                                 20 countries (Australasia, Asia,\                                Major CHD, major CVD and major cerebrovascular event (death from cerebrovascular disease and non-fatal stroke)                                                                                                                                 Mean age 66 years for both male and female                                             Both male and female       288/7502                                                                                                                                                                                                         HL χ^2^=19.9 (p=0.0004) (major event); HL χ^2^=32.7 (p\<0.0001) (any event)                                           AUC=0.587 (major event); AUC=0.567 (any event)
                                                                                                                                                                                           Europe, North America)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  D\'Agostino *et al*, (Framingham Stroke Risk)[@R37]              1                                 Costa *et al* [@R82]                                                                  Spain                                                            Stroke                                                                                                                                                                                                                                         55--85 years                                                                           Both male and female       9/178                                                                                                                                                                                                            NR                                                                                                                    NR

  Yang *et al*, (Hong Kong Diabetes Registry for Stroke)[@R38]     1                                 Yang *et al* [@R38]                                                                   Hong Kong                                                        Stroke                                                                                                                                                                                                                                         Median age 57 years                                                                    Both male and female       182/3541                                                                                                                                                                                                         The Life Table method, adequate calibration                                                                           Unadjusted AUROC=0.749 (0.716 to 0.782) and adjusted AUROC=0.776

  Mukamal *et al* [@R32]                                           2                                 Mukamal *et al* [@R32]                                                                USA                                                              MI, stroke, cardiovascular death                                                                                                                                                                                                               45--84 years                                                                           Both male and female       71/843                                                                                                                                                                                                           NR                                                                                                                    Basic model: C - statistic=0.65; basic model+CRP: C- statistic=0.66; basic model+CRP + (ABI, internal carotid wall thickness, ECG left ventricular hypertrophy): C-statistic=0.68

                                                                                                     Read *et al* [@R83]                                                                   Scotland                                                         Hospital admission or death from MI, stroke, unstable angina, transient ischaemic attack, peripheral vascular disease, and coronary, carotid, or major amputation procedures                                                                   30--89 years                                                                           Both male and female       14 081/181 399                                                                                                                                                                                                   Calibration plots: better calibration                                                                                 C-statistic=0.674 (0.669 to 0.679)

  Kiadaliri *et al* [@R22]                                         1                                 Kiadaliri *et al* [@R22]                                                              Sweden                                                           First and second events of: AMI, heart failure, non-acute IHD and stroke                                                                                                                                                                       Mean age 55.33 years (male) and 56.89 years (female)                                   Both male and female       NR/7259                                                                                                                                                                                                          HL χ^2^ statistic:\                                                                                                   C-statistic=0.79 (0.76 to 0.82) (first stroke)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              11.61 (p=0.17) (first stroke); 9.99 (p=0.27) (second stroke)                                                          C-statistic=0.70 (0.64 to 0.75) (second stroke)

  Davis *et al*, (Fremantle)[@R33]                                 2                                 Davis *et al* [@R33]                                                                  Australia                                                        CVD (hospitalisation for/with MI or stroke, and death from cardiac or cerebrovascular causes or sudden death)                                                                                                                                  Mean age 65.3 (35.9--89.0) years                                                       Both male and female       24/180                                                                                                                                                                                                           HL∧C -test, p=0.85, good calibration                                                                                  AUC=0.84 (0.76 to 0.91); p\<0.001

                                                                                                     Read *et al* [@R83]                                                                   Scotland                                                         Hospital admission or death from MI, stroke, unstable angina, transient ischaemic attack, peripheral vascular disease, and coronary, carotid or major amputation procedures                                                                    30--89 years                                                                           Both male and female       14 081/181 399                                                                                                                                                                                                   Calibration plots                                                                                                     C-statistic=0.665 (0.660 to 0.670)

  Kengne *et al*, (ADVANCE)[@R34]                                  2                                 Kengne *et al* [@R34]                                                                 16 countries                                                     CVD (fatal or non-fatal MI or stroke or cardiovascular death)                                                                                                                                                                                  Mean age 64.4 (8.1) years                                                              Both male and female       183/1836                                                                                                                                                                                                         HL test: p=0.032; predicted/observed risk=0.82                                                                        AUC=0.69 (0.646 to 0.724)

                                                                                                     Read *et al* [@R83]                                                                   Scotland                                                         Hospital admission or death from, stroke, unstable MI angina, transient ischaemic attack, peripheral vascular disease, and coronary, carotid, or major amputation procedures                                                                   30--89 years                                                                           Both male and female       14 081/181 399                                                                                                                                                                                                   Calibration plots                                                                                                     C-statistic=0.666 (0.661 to 0.671)

  Zethelius *et al* [@R35]                                         2                                 Zethelius *et al* [@R35]                                                              Sweden                                                           Fatal/non-fatal CVD (the composite of CHD or stroke)                                                                                                                                                                                           30--74 years                                                                           Both male and female       522/4906                                                                                                                                                                                                         P/O ratio=0.97, modified HL χ^2^ statistic=10.7 (p=0.2). Well calibration                                             C-statistic=0.72

                                                                                                     Read *et al* [@R83]                                                                   Scotland                                                         Hospital admission or death from MI, stroke, unstable angina, transient ischaemic attack, peripheral vascular disease, and coronary, carotid, or major amputation procedures                                                                   30--89 years                                                                           Both male and female       14 081/181 399                                                                                                                                                                                                   Calibration plots: better calibration                                                                                 C-statistic=0.663 (0.658 to 0.668)

  Stevens *et al*UKPDS 66[@R24]                                    1                                 Yao *et al* [@R84]                                                                    China                                                            CHD, stroke                                                                                                                                                                                                                                    30--79 years                                                                           Both male and female       Events (n) NR/1514                                                                                                                                                                                               NR                                                                                                                    NR

  Hippisley-Cox *et al*QRISK2[@R39]                                1                                 Read *et al* [@R83]                                                                   Scotland                                                         Hospital admission or death from MI, stroke, unstable angina, transient ischaemic attack, peripheral vascular disease, and coronary, carotid, or major amputation procedures                                                                   30--89 years                                                                           Both male and female       14 081/181 399                                                                                                                                                                                                   Calibration plots                                                                                                     C-statistic=0.674 (0.669 to 0.679)

  Elley *et al*NZ DCS[@R40]                                        1                                 Read *et al* [@R83]                                                                   Scotland                                                         Hospital admission or death from MI, stroke, unstable angina, transient ischaemic attack, peripheral vascular disease, and coronary, carotid, or major amputation procedures                                                                   30--89 years                                                                           Both male and female       14 081/181 399                                                                                                                                                                                                   Calibration plots: better calibration                                                                                 C-statistic=0.670 (0.665 to 0.674)

  Basu *et al*RECODe[@R36]                                         2                                 Basu *et al* [@R85]                                                                   USA                                                              Nephropathy (microalbuminuria, macroalbuminuria, renal failure, ESRD, reduction in glomerular filtration rate), moderate to severe diabetic retinopathy, fatal or non-fatal MI, fatal or non-fatal stroke, CHF and all-cause mortality         45--84 years (MESA),\                                                                  Both male and female       89 stroke (MESA), 142 stroke (JHS)/1555 (MESA), 1746 (JHS)                                                                                                                                                       Calibration slope=1.00, χ^2^=17.3, p value \<0.001 (MESA); calibration slope=1.05, χ^2^=22.9, p value \<0.001 (JHS)   C-statistic=0.75 for stroke (MESA); C-statistic=0.72 for stroke (JHS)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           35--84 years (JHS)                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                     Basu *et al* [@R36]                                                                   USA                                                              Microvascular: nephropathy, retinopathy, neuropathy; cardiovascular: composite of atherosclerotic CVD (first fatal or non-fatal MI or stroke), fatal or non-fatal MI, fatal or non-fatal stroke, CHF, or death from any cardiovascular cause   Mean age of 58.9 years                                                                 Both male and female       157/4760                                                                                                                                                                                                         Calibration slope for stroke=0.99, χ^2^=8.2, p value=0.22                                                             C-statistic for stroke=0.67 (0.63 to 0.71)

  Alrawahi *et al* [@R41]                                          1                                 Alrawahi *et al* [@R86]                                                               Oman                                                             Fatal and non-fatal CHD, stroke and\                                                                                                                                                                                                           Mean age 55.3±11.0 years (derivation sample) and 52.3±11.4 years (validation sample)   Both male and female       126 (derivation sample), 52 (validation sample /1314 (derivation sample), 405 (validation sample)                                                                                                                HL χ^2^ p value=0.15 (derivation sample) and HL χ^2^ p value=0.06 (validation sample). Satisfactory calibration       AUC=0.73 (0.69 to 0.77) (derivation sample); AUC=0.70 (0.59 to 0.75) (validation sample)
                                                                                                                                                                                                                                                            PAD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ABI, ankle--brachial index;ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation; AMI, acute myocardial infarction; AUC, area under the curve;AUROC, area under the receiver operating characteristic curve; CHD, coronary heart disease; CHF, congestive heart failure; CKD, chronic kidney disease; CRP, C reactive protein; CVD, cardiovascular disease; ESRD, end-stage renal disease; HL, Hosmer-Lemeshow; HLˆC, Hosmer-Lemeshow C-test; IHD, ischaemic heart disease;JHS, Jackson Heart Study; MESA, Multiethnic Study of Atherosclerosis; MI, myocardial infarction; NR, not reported;NZ DCS, New Zealand Diabetes Cohort Study; PAD, peripheral artery disease; P/O, predicted over observed; RAMP-DM, Multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus;RECODe, Risk Equations for Complications of Type 2 Diabetes; ROC, receiver operating characteristic;UKPDS, United Kingdom Prospective Diabetes Study.

UKPDS Risk Engine for Stroke by Kothari *et al* [@R21] was the most frequently externally validated model with a total of 12 studies reporting its performance in different diabetes cohorts. In 12 external validation studies, a total of 126 323 patients were included with considerable variations in sample sizes across the different studies. The pooled C-statistic for the model by Kothari *et al* [@R21] was 0.72 (95% CI, 0.68 to 0.75), with high heterogeneity identified (I^2^=95%; Cochran Q statistic p\<0.001). Stratification by sample size (small vs large, p=0.69), geographic location (Asia vs others, p=0.09) and stroke type (fatal vs non-fatal, p=0.07) did not explain the observed heterogeneity in the discriminative performance of this model. UKPDS Risk Engine by Stevens *et al* [@R26] was the second most externally validated model with five validation studies including 2826 patients. One study did not report the number of participants and none of the studies reported C-statistics. As a result, a pooled C-statistic and heterogeneity was not possible to assess for this model. The UKPDS Outcomes Model by Clarke *et al* [@R27] was externally validated by four studies including 65 056 patients. The pooled C-statistic was 0.66 (95% CI, 0.61 to 0.71) with high heterogeneity between studies (I^2^=84.5%; Cochran Q statistic p=0.002). Similar to the UKPDS Risk Engine for Stroke,[@R21] stratification across select study characteristics did not explain the observed heterogeneity. The Framingham risk score by Anderson *et al* [@R28] was externally validated in two studies including 8574 patients. The pooled C-statistic was 0.58 (95% CI, 0.54 to 0.61) with non-significant heterogeneity between studies (I^2^=56.1%; Cochran Q statistic p=0.102). The Framingham risk score by D'Agostino *et al* [@R29] was externally validated in two studies including 7604 patients. One study (Ataoglu *et al* [@R30]) did not report the C-statistic for the model and one study (Kengne *et al* [@R31]) reported two C-statistic values, one for major events and one for any event. The pooled C-statistic for these two values was 0.58 (95% CI, 0.55 to 0.60). Models by Mukamal *et al*.,[@R32] Davis *et al*.,[@R33] Kengne *et al* [@R34] and Zethelius *et al* [@R35] each were externally validated by two studies with pooled C-statistics of 0.67 (95% CI, 0.67 to 0.68), 0.75 (95% CI, 0.58 to 0.92), 0.67 (95% CI, 0.65 to 0.69) and 0.69 (95% CI, 0.63 to 0.75), respectively. Observed heterogeneity was high in models by Davis *et al* [@R33] and Zethelius *et al* [@R35] while low in models by Mukamal *et al* [@R32] and Kengne *et al*.[@R34] The model by Basu *et al* [@R36] was externally validated by two studies in three different population yielding a pooled C-statistic of 0.71 (95% CI, 0.67 to 0.76) with moderate heterogeneity between studies (I^2^=56.8%; Cochran Q statistic p=0.099).

Separate models by D\'Agostino *et al* (Framingham Stroke Risk Score),[@R37] Yang *et al* (Hong Kong Diabetes Registry for Stroke),[@R38] Kiadaliri *et al*,[@R22] Stevens *et al* (UKPDS 66),[@R24] Hippisley-Cox *et al* (QRISK2),[@R39] Elley *et al* (New Zealand Diabetes Cohort Study)[@R40] and Alrawahi *et al* [@R41] were each validated in one external or separate cohort with sample sizes ranging from 178 to 1 81 399 patients. For the studies that reported discrimination, C-statistics ranged from 0.67 to 0.79. In addition, calibration assessed by calibration plots and Hosmer-Lemeshow tests found good calibration in most studies.

The overall pooled C-statistic for all validation studies was 0.68 (95% CI, 0.67 to 0.70) with high heterogeneity between studies (I^2^=95.3%; Cochran Q statistic p\<0.001). Models that were developed in diabetes population showed significantly higher C-statistics than models developed in general populations (meta-regression p=0.001). Models, where stroke was reported as the main outcome as opposed to part of a composite CVD outcome, did show borderline significantly higher C-statistics (meta-regression p=0.052), although the value of the C-statistic is still low. This observed difference in the two models makes sense as models that include stroke as part of a composite outcome are expected to be different from models where stroke is the only outcome. A summary describing the characteristics of the studies where prediction models were developed in general populations but validated in patients with diabetes is presented in [table 5](#T5){ref-type="table"}.

Discussion {#s4}
==========

This systematic review and meta-analysis provides an overview of all stroke prediction models that were speciﬁcally developed for, or validated in patients with diabetes to calculate future stroke risk. Thirty-four stroke prediction models were identified that were speciﬁcally designed for patients with diabetes and only 32% of these prediction models have been externally validated, with varying results. Overall, the pooled C-statistics were poor for most models. Four of the prediction models identified were originally developed in the general population but externally validated in diabetes populations. The most notable prediction model was the UKPDS Risk Engine for Stroke[@R21] with 12 validation studies. Ten stroke prediction models had multiple validations, seven models had single validations and twenty-one had no validations at all. It is difficult to assess model performance for those with no validation or single validations. Additional validation studies on the performance of stroke prediction models in different diabetes populations are needed. Since stroke prediction models developed in the general population may not account for specific risk factors related to diabetes, using risk scores developed specifically in the diabetes population will help to estimate stroke risk among people with diabetes more accurately.

None of the models showed good discriminative performance consistently when externally validated. The model by Kothari *et al* [@R21] where the stroke was the primary outcome showed moderate discriminative performance (pooled C-statistic=0.72). Since this model was externally validated multiple times, the performance of this model can be considered as consistent. The discriminative ability of stroke prediction models where stroke was the primary outcome and models where stroke was a part of composite CVD outcome were modest, with C-statistics often less than 0.70.[@R42] Meta-analyses of the C- statistic suggests that there is significant between-study heterogeneity in the models where stroke is reported as the primary outcome and in those where stroke is reported as part of composite CVD outcome. Further, the possible sources of heterogeneity are unexplained. Perhaps the difference in patient characteristics in the different cohorts could be a potential source of heterogeneity; however, geographic location, sample size, follow-up time, external validation and variables included in the models were not significant sources of heterogeneity in meta-regression.

The discrimination of the 17 models that were validated were generally comparable with those observed in the development cohorts. However, the performance of some models externally validated in multiple cohorts was heterogeneous and possible source for this heterogeneity remains unexplained. There was also variability in prediction model quality and the methodology used in developing them. Our study findings suggest that, from a large number of published models in patients with diabetes, very few well-validated models are available for stroke prediction. This is helpful to inform the determination of models for clinical uptake when risk stratification approaches for stroke are implemented.

No evidence of small-study effects was detected, in which smaller studies reported better discrimination of models for predicting stroke. Study quality assessment shows many of the models failed to meet some key criteria: consideration of missing values, modelling assumptions, model validation and blinded outcome assessment, which is a concern. Many studies lacked standard reporting. This, to some extend, may be due to lack of guidelines for standards of reporting for risk prediction studies during that time. Many authors reported different aspects of prediction models, and in varying ways created difficulty in collecting information. The publication of new guidelines such as Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD)[@R43] has been introduced and may help improve reporting standards in subsequent studies in this area.

In prior reviews examining risk prediction models in adults with diabetes (Chamnan *et al* [@R44] van Dieren *et al*,[@R45] and Chowdhury *et al* [@R16]), all components of cardiovascular disease such as CHD, stroke, CAD, myocardial infarction, heart failure were considered as outcomes of the prediction model. Our review adds to knowledge on predicting risk of stroke in persons with diabetes in the following ways: (1) We only considered models where the primary outcome of the model was stroke or when stroke was part of a composite CVD outcome and corresponding C-statistic were provided; (2) We did not consider other components of CVD as outcomes of the model and therefore our estimates of model performance are more specific to stroke; (3) We have identified and included several recently derived models and conducted meta-analyses to explore reasons for variability in the discriminative performance across models and (4) We provide a detailed assessment of quality of studies among models developed in diabetes populations. Only one prior study[@R16] in this area performed a meta-analysis of model performance statistics across multiple studies or assessed study quality.

One of the major strengths of our study is the breadth of the systematic search, which included three different databases and extensive use of reference lists of the identified studies. Therefore, it is unlikely that any stroke prediction model-related studies have been missed. To best of our knowledge, this is the first study, where a meta-analysis and study quality assessment was performed on stroke prediction models in patients with diabetes. Nonetheless, there are few limitations in our study, which need to be kept in mind. In this paper, we only considered studies that developed or validated stroke prediction models within patients with diabetes. While prediction models for stroke have been developed for patients with other potential risk factors (eg, patients with hypertension), we felt that an exploration of a broad range of risk factors was outside the scope of this review. Though the inclusion of all stroke prediction models (regardless of the underlying risk factor(s)) could potentially improve the generalisability of our findings, it could have also increased the between-study heterogeneity, making the pooled estimates more difficult to interpret. We also did not consider non-English publications. Although, the English language is generally perceived to be the universal language of science, selection of research findings in a particular language can introduce language bias and may lead to erroneous conclusions. With this in mind, readers should to be cautious when interpreting the findings of our results. Finally, we were only able to use C-statistics to compare the model performance, which might be insensitive to identify differences in the ability of models to accurately risk-stratify patients into clinically meaningful risk groups.[@R46] In addition, meta-analysis of calibration measures (eg, E/O ratio) along with C-statistics could give a comprehensive summary of the performance of these models.

Our findings suggest that there is no significant difference between the discrimination of models where stroke was the primary outcome and stroke was part of composite CVD outcome. Models, particularly those that have never been validated or validated once need to undergo further external validation in which they will be used with or without recalibration or model updating to better understand the comparative performance of these models.

Conclusions {#s5}
===========

In conclusion, we have identiﬁed many models for predicting stroke in patients with diabetes and attempted to compare these models. Only a small number of models have undergone external validation and might provide generalisable predictions that would support their use in another clinical setting. It is difﬁcult to choose one model over another as none of these models exhibited superior discriminative performance, and unfortunately, no single model appears to perform consistently well. It could be argued that risk prediction in patients with diabetes is not essential. Persons with diabetes are generally perceived to be at elevated risk of stroke and the current practice is to treat to common HbA1C, blood pressure and low-density lipoprotein targets based on diabetes status alone and not on calculated risk. This non-risk based approach may be leading to unnecessary overtreatment and the absence of high-quality validated risk prediction models which limits our ability to assess whether more targeted approaches are possible. Further research is warranted to identify new risk factors with high associated relative risk to improve the currently available prediction models.
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